Ionis Pharmaceuticals (IONS) announced that it has entered a collaboration and license agreement with Novartis (NVS) for the discovery, development and commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven cardiovascular disease. This builds on the companies’ existing collaboration focused on the development and commercialization of pelacarsen, which Novartis is currently evaluating in a Phase 3 cardiovascular outcome study. The next generation compound will be a potential follow-on to pelacarsen.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IONS:
- Ionis Pharmacompletes enrollment for Phase 3 CARDIO-TTRansform study
- Ionis Pharmaceuticals upgraded to Buy from Neutral at Citi
- Ionis expands collaboration with AstraZeneca for eplontersen
- BridgeBio data positive for Alnylam and Ionis, says Citi
- Ionis Pharmaceuticals announces ‘positive’ results from Phase 3 NEURO-TTRansform
Questions or Comments about the article? Write to editor@tipranks.com